These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 8147063)

  • 1. [Rational therapy of heart failure].
    Werner MG; Schmieder RE
    Z Kardiol; 1993; 82 Suppl 4():7-16. PubMed ID: 8147063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indications for ACE inhibitors in chronic heart failure].
    Erdmann E
    Z Kardiol; 1994; 83 Suppl 4():75-9. PubMed ID: 7856285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of ACE inhibitors in heart failure (clinical aspects)].
    Riegger AJ
    Z Kardiol; 1992; 81 Suppl 4():93-6. PubMed ID: 1290309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
    Yusuf S
    Herz; 1993 Dec; 18 Suppl 1():444-8. PubMed ID: 8125425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of ACE inhibitors on urinary electrolyte secretion and the response to transitory hypovolemia in chronic heart failure].
    Marenzi G; Lauri G; Assanelli E; Grazi M; Guazzi M; Berna G; Salvioni A; Agostoni P
    Cardiologia; 1997 Dec; 42(12):1277-83. PubMed ID: 9534323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
    McNamara DM; Holubkov R; Postava L; Janosko K; MacGowan GA; Mathier M; Murali S; Feldman AM; London B
    J Am Coll Cardiol; 2004 Nov; 44(10):2019-26. PubMed ID: 15542286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H; Holmer SR; Riegger G
    Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Digoxin and angiotensin-converting enzyme inhibitors in the treatment of chronic congestive heart failure].
    Thery C
    Therapie; 1994; 49(3):211-8. PubMed ID: 7878586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current aspects of ACE inhibitor therapy from the cardiologic viewpoint].
    Klein W; Eber B; Gasser R; Stoschitzky K; Schumacher M; Fruhwald FM; Zweiker R
    Wien Med Wochenschr; 1996; 146(11):221-4. PubMed ID: 8928518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart failure: its progression and its therapy.
    Sonnenblick EH; LeJemtel TH
    Hosp Pract (Off Ed); 1993 Sep; 28(9):121-30. PubMed ID: 8366150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognosis of heart failure--value of drug therapy].
    Felix SB
    Z Kardiol; 1996; 85 Suppl 4():1-7. PubMed ID: 9027102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
    Roig E; Perez-Villa F; Morales M; Jiménez W; Orús J; Heras M; Sanz G
    Eur Heart J; 2000 Jan; 21(1):53-7. PubMed ID: 10610744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sympathetic activity in patients with heart failure due to idiopathic dilated cardiomyopathy: effect of ACE inhibitors and other vasodilators].
    Langes K; Bleifeld W
    Herz; 1990 Jun; 15(3):164-70. PubMed ID: 2198217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitors in congestive heart failure.
    Kantner TR
    J Fam Pract; 1992 Sep; 35(3):305-14. PubMed ID: 1517728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.